Bone loss and glucocorticoid therapy in patients with respiratory disease

Fairney, Angela
August 1999
Thorax;Aug1999, pS52
Academic Journal
No abstract available.


Related Articles

  • Monitor bone mass in patients taking glucocorticoids for obstructive lung disesase.  // Geriatrics;Feb2000, Vol. 55 Issue 2, p97 

    Deals with the management of glucocorticoid-induced bone loss in patients with chronic obstructive lung disease. Dosage of oral prednisone that causes bone loss; What a physical examination should assess; Types of drug to be prescribed to reduce the risk; Therapy that has shown to improve bone...

  • Secondary Osteoporosis in Patients with Juvenile Idiopathic Arthritis. Maresova, Kristyna Brabnikova // Journal of Osteoporosis;2011, p1 

    Bone disease in patients with juvenile idiopathic arthritis (JIA) is associatedwith focal (joint erosion and juxtaarticular osteopenia) and systemic bone loss (generalized osteopenia or reduction of bone mass density). Pathophysiology of bone loss is multifactorial and involves particularly...

  • Effect of Glucocorticoid Replacement Therapy on Bone Mineral Density in Patients with Addison Disease. Zelissen, Peter M.J.; Croughs, Ronald J.M.; van Rijk, Peter P.; Raymakers, Janthony A. // Annals of Internal Medicine;2/1/94, Vol. 120 Issue 3, p207 

    Investigates the influence of glucocorticoid replacement therapy on bone mineral density. Discussion of the cushing syndrome and pharmacologic administration of glucocorticoids; Characteristics of patients with Addison disease; Correlation between bone mineral density and plasma concentrations...

  • Chronic low-dose glucocorticoid inhalatory therapy as a cause of bone loss in a young man: case report. Capozzi, Anna; Casa, Silvia Della; Altieri, Barbara; Pontecorvi, Alfredo // Clinical Cases in Mineral & Bone Metabolism;2013, Vol. 10 Issue 3, p199 

    Osteoporosis in men is less frequent than in women and is more often due to an underlying cause, such as nutritional deficiencies or lifestyle factors, endocrinological or systemic affections, long-term specific therapies. The growing attention on male osteoporosis is mainly explained by the...

  • Dealing with osteoporosis.  // Dermatology Times;Apr95, Vol. 16 Issue 4, p66 

    Reports that 40% of patients on glucocorticoid therapy develop osteoporosis as a side effect of the drug. When bone loss occurs; Prevention of osteoporosis; DEXA scans; New developments in prevention.

  • A pharmacist can make a life-altering intervention. Guthrie, Ellen Whipple // Pharmacy Today;Mar2004, Vol. 10 Issue 3, p5 

    Reports on the role a pharmacist can play in protecting patients against osteoporosis. Continuous bone loss in steroid therapy and effects of glucocorticoid-induced osteoporosis; Ill effects of thyroid medications in patients with normal thyroid levels; Bone loss due to chemotherapeutic drugs...

  • Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids. Brask-Lindemann, D.; Eiken, P.; Eskildsen, P.; Abrahamsen, B. // Obstetrics & Gynaecology Forum;May2014, Vol. 24 Issue 2, p23 

    The article reports on the stud on alendronate prescription practices in Denmark. The study shows an increasing targeting of alendronate treatment in patients with chronic obstructive pulmonary disease (COPD) and an even stronger trend for patients with systemic glucocorticoid exposure. It notes...

  • Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. Suzuki, Yasuo; Nawata, Hajime; Soen, Satoshi; Fujiwara, Saeko; Nakayama, Hisanori; Tanaka, Ikuko; Ozono, Keiichi; Sagawa, Akira; Takayanagi, Ryoichi; Tanaka, Hiroyuki; Miki, Takami; Masunari, Naomi; Tanaka, Yoshiya // Journal of Bone & Mineral Metabolism;Jul2014, Vol. 32 Issue 4, p337 

    In this article, the author discusses treatment and management of glucocorticoid (GC) induced osteoporosis which is widely used to treat various inflammatory and immunologic that cause rheumatic, respiratory, and skin diseases. Topics discussed include cohort analysis on Japanese patients with...

  • Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis. Dore, Robin K. // Patient Preference & Adherence;2013, Vol. 7, p435 

    Glucocorticoids are commonly prescribed medications to treat multiple diseases across many medical specialties. One of the most common yet largely unappreciated side effect of glucocorticoid use is increased risk of fracture. Many different therapies are indicated to prevent and treat this...

  • Glucocorticoids in Patients with Rheumatic Diseases: Friends or Enemies of Bone? Ciccarelli, Fedra; De Martinis, Massimo; Ginaldi, Lia // Current Medicinal Chemistry;Feb2015, Vol. 22 Issue 5, p596 

    Increased bone resorption and enhanced risk of osteoporotic fractures are often reported in patients with diseases having immune system involvement, mainly inflammatory rheumatic diseases, for which glucocorticoids are more often prescribed because of their powerful antinflammatory effects....


Read the Article


Sign out of this library

Other Topics